ArticleBMC pulmonary medicine2024

Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-tyrosine kinase inhibitors: a retrospective dual-center study.

Kan Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.